PROSTATE CANCER WITH A HIGH BASELINE PSA LEVEL AFTER COMBINED TREATMENT
https://doi.org/10.17709/2409-2231-2017-4-4-14
Abstract
This article describes a rare clinical case of prostate cancer with a high baseline PSA level of 1407 hg/ml. In the course of diagnosis, hormonal and surgical treatment there was a successive dynamics of PSA decline: 07.08.2015–1407 ng/ ml, 14.09.2015–43,61ng/ml; 17.11.2015–0,326 ng/ml; 13.02.2016 (end of hormone therapy) — 0,084 ng/ml. After the operation of radical prostatectomy with enlarged lymphadenectomy, on 20.04.2016 (with prolonged hormone therapy up to 9 monthes) gradual decrease of PSA level continued: 05.05.2016–0,008 ng/ml; 17.06.2016–0,008 ng/ml; 08.09.2016–0,039 ng/ml; 30.11.2016–0,002 ng/ml; 07.09.2017 (total PSA) — 0,008 ng/ml. In parallel, there was a consistent improvement in the clinical picture, up to the MRI data of 19.10.2017, when there were no significant neoplastic changes at the level of the study (in the projection of the prostatic bed).
About the Authors
A. T. Asratov
P. Hertsen Moscow Oncology Research Institute – Branch of the National Medical Radiology Research Centre of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
Asad T. Asratov postgraduate of oncourological Department.
3, 2nd Botkinskiy proezd, Moscow, 125284
A. S. Kalpinskiy
P. Hertsen Moscow Oncology Research Institute – Branch of the National Medical Radiology Research Centre of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
Alexey S. Kalpinskiy - PhD, senior researcher of oncourological Department.
3, 2nd Botkinskiy proezd, Moscow, 125284
I. A. Taraki
P. Hertsen Moscow Oncology Research Institute – Branch of the National Medical Radiology Research Centre of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
Ivad A. Taraki - clinical intern of Department of urology and surgical nephrology with the course of oncourology PFUR.
3, 2nd Botkinskiy proezd, Moscow, 125284
Yu. V. Samsonov
P. Hertsen Moscow Oncology Research Institute – Branch of the National Medical Radiology Research Centre of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
Yurii V. Samsonov - PhD, leading researcher of Russian Center of Informational Technologies and Epidemiological Research in Oncology.
3, 2nd Botkinskiy proezd, Moscow, 125284
A. A. Kostin
P. Hertsen Moscow Oncology Research Institute – Branch of the National Medical Radiology Research Centre of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
Andrey A. Kostin - MD., professor, head of department of urology, oncology and radiology of FAS, Medical institute, PFUR, First Deputy General Director NMRRCMHRF.
3, 2nd Botkinskiy proezd, Moscow, 125284
References
1. Kaprin AD, Starinskii VV, Petrova GV. Malignant neoplasms in Russia in 2014. Мoscow: P. Hertsen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Centre, 2015, p. 25–27, 31,130–133 Available at: http://www.oncology.ru/service/statistics/malignant_tumors/2014.pdf (In Russian).
2. Sostoyanie onkologicheskoi pomoshchi naseleniyu Rossii v 2015 godu [The state of oncological care for the population of Russia in 2015]. Ed by Kaprin AD, Starinskii VV, Petrova GV. Мoscow: P. Hertsen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Centre, 2016, 236 p. Available at: http://oncology-association.ru/docs/medstat/sostoyznie/2015.pdf (In Russian).
3. Bogomolov OA, Zharinov GM, Shkolnik MI. Dynamics of prostate-specific antigen concentration — growth kinetics of prostate cancer? Voprosy oncologii (Problems in Oncology). 2014; 60 (4): 437–448. (In Russian).
4. Matveev BP, Matveev VB, Davydov MI, et al. Klinicheskaya onkourologiya [Clinical oncourology]. Ed by Matveev BP. Мoscow: Russian society of oncourologists, 2011, 936 p. (In Russian).
5. Urologiya [Urology]. Ed by Lopatkin NA. Moscow: «GEOTAR-Media» Publ., 2011, 1024 p. (In Russian).
6. Heidenreich A. et al. Guidelines on Prostate Cancer. In: EAU Guidelines, ed. presented at 25th EAU Annual Congress. Barcelona, 2010.
7. Stamey TA, Kabalin JN, McNeal JE. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients. J Urol. 1989; 141 (5): 1076–83. https://doi.org/10.1016/S0022–5347(17)41175-X
Review
For citations:
Asratov A.T., Kalpinskiy A.S., Taraki I.A., Samsonov Yu.V., Kostin A.A. PROSTATE CANCER WITH A HIGH BASELINE PSA LEVEL AFTER COMBINED TREATMENT. Research and Practical Medicine Journal. 2017;4(4):133-142. (In Russ.) https://doi.org/10.17709/2409-2231-2017-4-4-14
Views:
1896
Email this article 